Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213277 | 1.00 | KMT2A (0.46) | KMT2AMEN1NPSR1KDM4EALDH1A1 | |
| SCHEMBL15377187 | 0.94 | KMT2A (0.48) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL1843672 | 0.94 | KMT2A (0.48) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL528451 | 0.76 | ALDH1A1 (0.39) | KMT2AMEN1NPSR1KDM4EALDH1A1 | |
| SCHEMBL528115 | 0.76 | ALDH1A1 (0.39) | KMT2AMEN1NPSR1KDM4EALDH1A1 | |
| SCHEMBL874199 | 0.75 | KDM4E (0.70) | KMT2AMEN1NPSR1KDM4EALDH1A1 | |
| SCHEMBL528906 | 0.74 | ALDH1A1 (0.37) | KMT2AMEN1NPSR1KDM4EALDH1A1 | |
| SCHEMBL528905 | 0.74 | ALDH1A1 (0.37) | KMT2AMEN1NPSR1KDM4EALDH1A1 | |
| SCHEMBL528034 | 0.73 | MMP2 (0.44) | KMT2AMEN1ALDH1A1GAAGPR139 | |
| SCHEMBL528033 | 0.73 | MMP2 (0.44) | KMT2AMEN1ALDH1A1GAAGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846910-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-09-30 | — | — | US | disclosed |
| US-8816073-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-08-26 | — | — | US | disclosed |
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-14 | — | — | US | disclosed |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-07 | — | — | US | disclosed |
| US-8507670-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2013-08-13 | — | — | US | disclosed |
| EP-2598493-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-06-05 | — | — | EP | disclosed |
| EP-2074093-B1 | PROCESS FOR PREPARING MATRIX METALLOPROTEINASE INHIBITORS AND CHIRAL AUXILIARY THEREFOR | RANBAXY LAB LTD (IN) | 2012-10-10 | — | — | EP | disclosed |
| EP-2474531-A2 | Matrix metalloproteinase inhibitors | Ranbaxy Laboratories Limited (IN) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012014114-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
| EP-2322507-A1 | Matrix metalloproteinase inhibitors | Ranbaxy Laboratories Limited (IN) | 2011-05-18 | — | — | EP | disclosed |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2010-04-01 | — | — | US | disclosed |
| EP-2074093-A2 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008023336-A2 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | KMT2A 2541/4885MEN1 3336/4885NPSR1 2513/4885 |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | KMT2A 2541/4885MEN1 3336/4885NPSR1 2513/4885 |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP12 | KMT2A 2765/4885MEN1 3212/4885NPSR1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.